CHINARES PHARMA (03320): KPC Pharmaceuticals, Inc.'s shareholders' net profit in 2025 is expected to be approximately 350 million yuan, a decrease of 46% year-on-year.

20:07 19/03/2026

China Resources Pharmaceuticals (03320) announced the performance of Kun Pharmaceutical Group in 2025. The total operating income is approximately 6.575 billion yuan, a decrease of 21.74% year-on-year. The net profit attributable to shareholders of the listed company is about 350 million yuan, a decrease of 46% year-on-year. Earnings per share is 0.46 yuan, and a cash dividend of 1.80 yuan (including tax) is distributed for every 10 shares held.

CHINARES PHARMA (03320) announced the performance of KPC Pharmaceuticals, Inc. in 2025, with total operating revenue of approximately 6.575 billion yuan, a year-on-year decrease of 21.74%; the net profit attributable to shareholders of the listed company is approximately 350 million yuan, a year-on-year decrease of 46%; basic earnings per share is 0.46 yuan, and the dividend is 1.80 yuan per 10 shares (including tax).

VICTORY SEC (08540) announced its performance for 2025. The company's owners should enjoy a net profit of 60.36 million Hong Kong dollars, turning losses into profits year-on-year.

GOLDPAC GROUP (03315) will distribute a special dividend of HK$0.01 per share on June 17th.

GOLDPAC GROUP (03315) will distribute a final dividend of HK$0.04 per share on June 17th.

VICTORY SEC (08540) announced its performance for 2025. The company's owners should enjoy a net profit of 60.36 million Hong Kong dollars, turning losses into profits year-on-year.

GOLDPAC GROUP (03315) will distribute a special dividend of HK$0.01 per share on June 17th.

GOLDPAC GROUP (03315) will distribute a final dividend of HK$0.04 per share on June 17th.